Diabetes mellitus type 2 diagnostic study of choice

Revision as of 19:33, 17 January 2019 by Trushatank (talk | contribs)
Jump to navigation Jump to search

Diabetes mellitus main page

Diabetes mellitus type 2 Microchapters

Home

Patient information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Diabetes Mellitus Type 2 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical therapy

Life Style Modification
Pharmacotherapy
Glycemic Control

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Diabetes mellitus Main page

Patient Information

Type 1
Type 2

Overview

Classification

Diabetes mellitus type 1
Diabetes mellitus type 2
Gestational diabetes

Differential Diagnosis

Complications

Screening

Diagnosis

Prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Trusha Tank, M.D.[2]

Overview

The diagnostic test of choice for diabetes mellitus is fasting plasma glucose (FPG). According to the ADA criteria, diabetes mellitus is diagnosed with FPG ≥126 mg/dL (7.0 mmol/L). Other diagnostic findings consistent with the diagnosis of type 1 DM include 2-h PG ≥200 mg/dL (11.1 mmol/L) during an OGTT, or A1C ≥6.5% (48 mmol/mol), or classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L).

Diagnostic study of choice

Diagnostic study of choice for diabetes mellitus is fasting plasma glucose (FPG). According to the ADA criteria, diabetes mellitus is diagnosed with FPG ≥126 mg/dL (7.0 mmol/L). [1][2]

Diagnostic criteria

ADA criteria for the diagnosis of type 1 DM follows:[1][2][3]

ADA Criteria for the diagnosis of diabetes
FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h.*
OR
2-h PG ≥200 mg/dL (11.1 mmol/L) during an OGTT. The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.*
OR
A1C ≥6.5% (48 mmol/mol). The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.*
OR
In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L).
  •  In the absence of unequivocal hyperglycemia, results should be confirmed by repeat testing.


References

  1. 1.0 1.1 Nguyen Q, Nguyen L, Felicetta J (October 2008). "Evaluation and management of diabetes mellitus". Am Health Drug Benefits. 1 (8): 39–48. PMC 4106505. PMID 25126259.
  2. 2.0 2.1 "Standards of medical care in diabetes--2008". Diabetes Care. 31 Suppl 1: S12–54. January 2008. doi:10.2337/dc08-S012. PMID 18165335.
  3. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, Metzger BE, Nathan DM (June 2011). "Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus". Diabetes Care. 34 (6): e61–99. doi:10.2337/dc11-9998. PMC 3114322. PMID 21617108.